Patents by Inventor Matthias Zeis

Matthias Zeis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Identification of Hla-A2-presented T-cell epitopes derived from the oncofoetal antigen-immature laminin receptor protein and uses thereof
    Patent number: 7968097
    Abstract: The present invention relates to the immunotherapB of cancer, in particular several tumor entities including hematological malignancies. The present invention relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. In particular, the present invention relates to two novel peptide sequences derived from HLA class I or II molecules of human oncofoetal antigen immature laminin receptor (OFA/iLR), which can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: April 26, 2006
    Date of Patent: June 28, 2011
    Assignee: Immatics Biotechnologies GmbH
    Inventor: Matthias Zeis
  • Identification of Hla-A2-Presented T-Cell Epitopes Derived from the Oncofoetal Antigen-Immature Laminin Receptor Protein and Uses Thereof
    Publication number: 20090041794
    Abstract: The present invention relates to the immunotherapB of cancer, in particular several tumor entities including hematological malignancies. The present invention relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. In particular, the present invention relates to two novel peptide sequences derived from HLA class I or II molecules of human oncofoetal antigen immature laminin receptor (OFA/iLR), which can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: April 26, 2006
    Publication date: February 12, 2009
    Applicant: Immatics Biotechnologies GmbH
    Inventor: Matthias Zeis